Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients

Zinger, A; Latham, SL; Combes, V; Byrne, S; Barnett, MH; Hawke, S; Grau, GE

Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients

Zinger, A Latham, SL Combes, V

Byrne, S Barnett, MH Hawke, S Grau, GE

Permalink

Publication Type:: Journal Article
Citation:: Multiple Sclerosis, 2016, 22 (14), pp. 1883 - 1887
Issue Date:: 2016-01-01

Closed Access

	Filename	Description	Size
	MSJ636959.pdf	Accepted Manuscript Version	604.32 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Zinger, A	en_US
dc.contributor.author	Latham, SL	en_US
dc.contributor.author	Combes, V https://orcid.org/0000-0003-2178-3596	en_US
dc.contributor.author	Byrne, S	en_US
dc.contributor.author	Barnett, MH	en_US
dc.contributor.author	Hawke, S	en_US
dc.contributor.author	Grau, GE	en_US
dc.date.available	2016-02-10	en_US
dc.date.issued	2016-01-01	en_US
dc.identifier.citation	Multiple Sclerosis, 2016, 22 (14), pp. 1883 - 1887	en_US
dc.identifier.issn	1352-4585	en_US
dc.identifier.uri	http://hdl.handle.net/10453/54931
dc.description.abstract	© The Author(s), 2016. Background: No molecular marker can monitor disease progression and treatment efficacy in multiple sclerosis (MS). Circulating microparticles represent a potential snapshot of disease activity at the blood brain barrier. Objectives and methods: To profile plasma microparticles by flow cytometry in MS and determine how fingolimod could impact endothelial microparticles production. Results: In non-treated MS patients compared to healthy and fingolimod-treated patients, endothelial microparticles were higher, while B-cell-microparticle numbers were lower. Fingolimod dramatically reduced tumour necrosis factor (TNF)-induced endothelial microparticle release in vitro. Conclusion: Fingolimod restored dysregulated endothelial and B-cell-microparticle numbers, which could serve as a biomarker in MS.	en_US
dc.relation.ispartof	Multiple Sclerosis	en_US
dc.relation.isbasedon	10.1177/1352458516636959	en_US
dc.subject.classification	Neurology & Neurosurgery	en_US
dc.subject.mesh	Endothelium, Vascular	en_US
dc.subject.mesh	B-Lymphocytes	en_US
dc.subject.mesh	Endothelial Cells	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Multiple Sclerosis	en_US
dc.subject.mesh	Immunosuppressive Agents	en_US
dc.subject.mesh	Adult	en_US
dc.subject.mesh	Middle Aged	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Male	en_US
dc.subject.mesh	Cell-Derived Microparticles	en_US
dc.subject.mesh	Fingolimod Hydrochloride	en_US
dc.title	Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients	en_US
dc.type	Journal Article
utslib.citation.volume	14	en_US
utslib.citation.volume	22	en_US
utslib.for	1103 Clinical Sciences	en_US
utslib.for	1109 Neurosciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	closed_access
pubs.issue	14	en_US
pubs.publication-status	Published	en_US
pubs.volume	22	en_US

Abstract:

© The Author(s), 2016. Background: No molecular marker can monitor disease progression and treatment efficacy in multiple sclerosis (MS). Circulating microparticles represent a potential snapshot of disease activity at the blood brain barrier. Objectives and methods: To profile plasma microparticles by flow cytometry in MS and determine how fingolimod could impact endothelial microparticles production. Results: In non-treated MS patients compared to healthy and fingolimod-treated patients, endothelial microparticles were higher, while B-cell-microparticle numbers were lower. Fingolimod dramatically reduced tumour necrosis factor (TNF)-induced endothelial microparticle release in vitro. Conclusion: Fingolimod restored dysregulated endothelial and B-cell-microparticle numbers, which could serve as a biomarker in MS.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/54931